Skip to Main Content

++

INTRODUCTION

++

beractant (be-rak-tant)

Survanta

Classification

Therapeutic: anti-RDS agents

Pharmacologic: pulmonary surfactants

++
Indications
++

Treatment and prophylaxis of respiratory distress syndrome (RDS, hyaline membrane disease) in premature infants.

++
Action
++

Replaces endogenous pulmonary surfactant in premature infants, allowing normal surface activity in alveoli. Consists of natural bovine lung extract. Therapeutic Effects: Decreased incidence, mortality, and complications from RDS.

++
Adverse Reactions/Side Effects
++

Resp: oxygen desaturation (as a result of administration process). CV: transient bradycardia.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor oxygen saturation levels following administration. Notify physician or nursing staff immediately about a sudden decrease is oxygen saturation.

  • Assess heart rate, and report a sustained decrease in heart rate (bradycardia).

++
Interventions
++

  • When indicated, implement chest physical therapy interventions such as positioning, suctioning, and chest percussion/vibration to maintain respiratory function and augment drug effects in premature infants.

++
Pharmacokinetics
++

Absorption: Administered directly to site of action. Systemic absorption not known.

++

Distribution: Rapidly distributes to lung tissue.

++

Metabolism and Excretion: Enters surfactant pathways in which recycling and reutilization occur.

++

Half-life: Unknown.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (improved oxygenation)

ROUTE ONSET PEAK DURATION
intratracheal within min unknown unknown

++
Contraindications/Precautions
++

Contraindicated in: No known contraindications.

++

Use Cautiously in: No known cautions. Nosocomial infections may be more common.

++
Interactions
++

Drug-Drug: None known.

++
Route/Dosage
++

Intratracheal (Infants, Premature): 100 mg phospholipids/kg birth weight (4 mL/kg birth weight); 4 doses may be given in first 48 hr of life, no closer than q 6 hr apart.

++
Availability
++

Intratracheal suspension: 25 mg phospholipid/mL—4-mL and 8-mL vials.

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.